CopilotIQ / Biofourmis

CopilotIQ / Biofourmis

The 2024 merger of CopilotIQ and Biofourmis created a combined entity uniting CopilotIQ's remote monitoring technologies for chronic conditions with Biofourmis's FDA-cleared AI analytics and hospital-at-home platform. The transaction brought together distinct patient-monitoring datasets and regulatory clearances under a single operational roof. The merged firm targets US health systems and payers with a vertically integrated service that spans in-hospital virtual wards, post-acute care transitions, and long-term chronic disease management. The platform combines FDA-cleared wearable biosensors with machine-learning algorithms designed to predict clinical deterioration before it happens. Asset-class exposure runs through venture-backed growth equity, with investors including General Atlantic, CVS Health Ventures, and Openspace Ventures (per public record, 2023–2024). The firm operates across the United States and maintains a presence in Singapore via Biofourmis's legacy Asia-Pacific operations. Its pipeline covers cardiology, orthopedics, and post-surgical recovery programs sold directly to integrated delivery networks. Headcount details remain private, though Biofourmis employed approximately 500 people pre-merger (per public record, 2023). CopilotIQ operated a smaller US-based clinical operations team focused on nursing and remote-care coordination. The merger eliminated management duplication and is designed to create a single operating platform with combined FDA 510(k) clearances for multiple care settings. In 2024 the merged entity integrated its commercial contracting teams under a unified leadership structure (per the firm's official communications). The structural differentiator is the firm's regulatory posture: Biofourmis holds multiple FDA clearances for AI-based physiological signal analysis, placing the combined entity in a regulatory moat that is difficult for pure-software entrants to replicate. The merged company can bill Medicare for remote physiologic monitoring while simultaneously deploying machine-learning algorithms that operate under FDA enforcement discretion during active clinical validation. This dual revenue model — software-as-a-service plus reimbursable clinical services — creates a capital structure distinct from venture-backed digital health peers.